This Universal Ibogaine profile is part of a paid investor education campaign.*

Overview

Universal Ibogaine is a Canadian company working to develop compounds to combat the opioid epidemic through plant-based medicine. The company aims to operate and franchise clinics around the world, offering ibogaine as a treatment for opioid-based withdrawals.

Opioids can be found in a number of licit and illicit forms. A number of opioid medications, including codeine, fentanyl, morphine, oxycodone and diacetylmorphine are produced and used most often to treat pain. Problematic opioid use generally occurs when a patient strays from their prescription or the instructions provided by a doctor or pharmacist. Substance abuse and/or opioid dependence can occur when someone regularly uses drugs or alcohol despite continued negative consequences.

The company has provided treatment to over 3400 patients. Universal Ibogaine operates a safe and effective seven-day treatment program using ibogaine, a psychoactive alkaloid extracted from the root bark of Tabernanthe iboga, a Central West African rain forest shrub.

While Ibogaine is not currently authorized for use by Health Canada, the company intends to pursue clinical trials of the drug in 2020. Studies have shown the potential for opioid detoxification with ibogaine, with evidence that suggests a lack of withdrawal symptoms after a single dose. “Individuals typically do not go back into withdrawal following opioid detoxification with single doses of ibogaine despite opioid abstinence, suggesting a persistent modification of neuroadaptations associated with opioid tolerance or dependence,” said Tamara Antonio in the study “Effect of Iboga Alkaloids on µ-Opioid Receptor-Coupled G Protein Activation.” Ibogaine is currently a Schedule I substance according to the US Drug Enforcement Agency.

Universal Ibogaine Inc. has entered into a letter of agreement to conduct a reverse-takeover of P Squared Renewables (TSXV:PSQP), allowing the company to list on the TSX Venture. If approved, the merged company is expected to be renamed Clear Sky Addiction Solutions Inc. In concert with the company listing on the TSX, Universal Ibogaine intends to complete a financing of C$5 million.

Universal Ibogaine’s Company Highlights

• Aiming to be listed on the TSX Venture Exchange in 2020
• Provided ibogaine treatment to over 3400 patients through the Clear Sky Recovery center
• Treatment follows a proven three-step approach: stabilize, detox, and rehabilitate
• RTO of P Squared Renewables planned for 2020, re-listing as Clear Sky Addiction Solutions

Clearsky Addiction Solutions

Moving forward, Universal Ibogaine Inc. intends to raise C$5 million by issuing approximately 20 million units. The funding is intended to be put towards the completion of the company’s RTO of P Squared Renewables. The newly-named company, Clear Sky Addiction Solutions, intends to complete the acquisition of its next treatment clinic and finalize the acquisition of a property in Belize.

Clearsky Addiction Solutions intends to conduct clinical trials in Canada in 2021 with plans to implement a global medical tourism marketing plan to showcase its treatment centers.

Clear Sky Recovery Clinic

Universal Ibogaine Inc. has acquired the exclusive licensing rights from Clear Sky Recovery Cancun, an ibogaine treatment center in Cancun, Mexico. The facility has provided over 3400 treatments using a proven protocol including treatments of ibogaine designed to ease the withdrawal symptoms associated with a variety of addictive drugs including heroin, OxyContin & Oxycodone, methadone, buprenorphine (Subutex and Suboxone), cocaine, methamphetamine and alcohol. According to the company, ibogaine has the potential to eliminate 95 percent of symptoms associated with opioid withdrawal.

The facility’s treatment protocols are designed to meet the specific needs of individual patients and their unique medical background. The facility is an oceanfront private hospital located in the Punta Sam resort area of beautiful Cancún that aims to provide a safe and effective setting for ibogaine treatment for interrupting drug dependency disorders. Clear Sky provides a comprehensive pre-care and aftercare package that can be customized to cater to a patient’s unique needs.

Over the last 13 years, Dr. Alberto Sola has treated thousands of patients at Clear Sky Recovery. He believes ibogaine has significant potential in combating drug dependency issues. “We have a once in a lifetime to help the sufferers of a modern-day epidemic, the opioid crisis, by bringing them a safe and effective, seven-day treatment with ibogaine. It’s an opportunity to save lives, change paradigms in the addiction industry and pioneer a brand new market.”

Universal Ibogaine’s Management Team

Dr. Alberto Sola, BSc, MD 

Clear Sky Addiction Solution’s President, Dr Sola is a thought leader in entheogenic treatment. He has the distinction of having treated more patients with ibogaine than any other person in the world and is head of operations at Clear Sky Recovery. Dr. Sola graduated from Universidad Anahuac. As the Medical Director of Amerimed, he opened four emergency hospitals for tourists in Puerto Vallarta, Cancun, and Cabo San Lucas.

Dr. William Dick

Dr. Dick is a practicing emergency medicine physician and clinical researcher based at the University of British Columbia. He has extensive administrative and front-line experience in substance use disorder policy and treatment. Dr. Dick’s research work includes novel pain control methods, cardiac resuscitation and emergency health system redesign. In his previous position as Vice-President Medical Programs, BC Emergency Health Services, he worked closely with governments, public health agencies and frontline health providers to help facilitate the provincial response to the current opioid overdose epidemic.

Hirpal Hundial, RN, BSN, MSN

Hirpal Hundial is a Registered Nurse and Nursing Practice Consultant with a background in critical care. She has worked closely with the B.C. Supreme Court on numerous occasions regarding patient safety, designed the Safe Care Nursing Framework, and is a patient safety educator certified by the Canadian Patient Safety Institute.

Universal Ibogaine’s Board of Directors

Shayne Nyquvest

Shayne Nyquvest is the former Executive Vice President of Mackie Research Capital and a founding member of the Canaccord Genuity Group. Nyquvest can personally vouch for the transformational effects of ibogaine and aims to see this treatment adopted by the mainstream medical community as an answer to the opioid epidemic.

Dr. Alberto Sola, BSc, MD 

Clear Sky Addiction Solution’s President, Dr Sola is a thought leader in entheogenic treatment. He has the distinction of having treated more patients with ibogaine than any other person in the world and is head of operations at Clear Sky Recovery. Dr. Sola graduated from Universidad Anahuac. As the Medical Director of Amerimed, he opened four emergency hospitals for tourists in Puerto Vallarta, Cancun, and Cabo San Lucas.

Chief Ian Campbell, MBA

Chief Ian Campbell is a hereditary chief of the Squamish Nation located in Vancouver, British Columbia. He has served as an elected member of council since 2005, and was appointed as a Political Spokesperson in 2008. Since 1999 he has been the Cultural Ambassador and Negotiator for the Intergovernmental Relations Department of the Squamish Nation, advancing Aboriginal rights and title, while invigorating substantive economic opportunities through negotiations, collaboration, and partnerships.

Robert Turner BSc, MBA, ICD.D

Mr. Turner is President of his own incorporated consulting firm and a Principal within Western Management Consultants (WMC). His consulting focus is providing guidance to Boards on their governance including proper CEO oversight. Mr. Turner brings experience as a CHRO in both the private and public sectors. Subsequently, he joined Mercer Canada as a Partner focused on consulting within Canadian health care. Robert has served on Universal Ibogaine’s Advisory Board since December 2018. Robert has an ICD.D certification from Rotman Business School, an MBA from the Ivey Business School and a BSc (Biochemistry) from the University of Toronto. He serves on the Boards of two other corporations – one private and one not-for-profit.

Jeremy Weate, PhD

Jeremy Weate has over 16 years strategic advisory experience, focused on minister-level guidance on natural resource governance across over 50 projects in over 30 countries in Europe, Africa, Central Asia and the South Pacific. Dr Weate has a decade-long interest in ibogaine, which has seen him serve as Executive Director of the Global Ibogaine Therapy Alliance and as a director of Ibogaine For The World, a Canadian-registered non-profit. He has co-organized ibogaine conferences in Vienna and Porto. He is also executive producer of The Ibogaine Stories, a documentary film about ibogaine, currently in production. In 2018, he helped set up Tabula Rasa Retreat in Portugal, now of the leading ibogaine treatment facilities globally.

---

This profile is sponsored by Universal Ibogaine. This profile provides information which was sourced by the Investing News Network (INN) and approved by Universal Ibogaine, in order to help investors learn more about the company. Universal Ibogaine is a client of INN. The company’s campaign fees pay for INN to create and update this profile.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Universal Ibogaine and seek advice from a qualified investment advisor.